Local Anesthetic Infiltration and Infusion for Pain Control After Hip Replacement
NCT ID: NCT01409278
Last Updated: 2011-08-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
105 participants
INTERVENTIONAL
2009-08-31
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. One time injection of ropivacaine before wound closure
2. One time injection of ropivacaine before wound closure plus slow release of ropivacaine via catheter for 48 hours
3. Standard practice of patient controlled pump
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Local Infiltration Analgesia in Total Hip Arthroplasty
NCT00968955
Pain Management Following Total Hip Arthroplasty
NCT02568995
The Analgesic Efficacy of Periarticular Infiltration of Local Anaesthetic for Total Hip Replacement
NCT01312077
Use of Local Infiltration Analgesia Following Total Hip Arthroplasty
NCT01344395
Intraarticular Analgesia After Total Hip Arthroplasty, a Randomised Study
NCT00289419
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ropivacaine infiltration and infusion.
Ropivicaine infiltration followed by continuous ropivicaine infusion for 48 hours.
Ropivacaine infiltration and infusion.
50 ml infiltration of ropivacaine 0.2% and ketorolac 15mg admixture followed by ropivacaine 0.2 % at 5ml per hour infusion for 48 hours.
Ropivacaine and Saline
Ropivicaine infiltration followed by normal saline infusion.
Ropivacaine infiltration and saline infusion.
50ml ropivacaine 0.2% with keterolac 15mg infiltration followed by normal saline infusion at 5ml per hour
Saline infiltration and infusion.
Normal saline infiltration followed by saline infusion.
Normal Saline
50ml of normal saline infiltration followed by normal saline infusion at 5ml per hour
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ropivacaine infiltration and saline infusion.
50ml ropivacaine 0.2% with keterolac 15mg infiltration followed by normal saline infusion at 5ml per hour
Ropivacaine infiltration and infusion.
50 ml infiltration of ropivacaine 0.2% and ketorolac 15mg admixture followed by ropivacaine 0.2 % at 5ml per hour infusion for 48 hours.
Normal Saline
50ml of normal saline infiltration followed by normal saline infusion at 5ml per hour
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Trinity Health Of New England
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Saint Francis Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sanjay Sinha, M.D.
Role: PRINCIPAL_INVESTIGATOR
Saint Francis Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Saint Francis Hospital and Medical Center
Hartford, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-07-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.